摘要
目的探讨黄芪多糖注射液联合吉非替尼对肺癌患者组织中P53及Ki-67蛋白表达的影响。方法选取非小细胞肺癌患者67例,按治疗方法不同分组,对照组28例口服吉非替尼,研究组39例在吉非替尼基础上加用黄芪多糖注射液,免疫组化法测定治疗前后组织Ki-67及P53蛋白水平,同时测定T淋巴细胞亚群变化。结果研究组有效率、疾病控制率与对照组比较差异无统计学意义。研究组治疗后P53阳性率显著高于对照组,Ki-67阳性率显著低于对照组(均P<0.05)。研究组治疗后CD3^+T、CD4^+T低于对照组,CD8^+T、CD4^+T/CD8^+T高于对照组(均P<0.05)。结论采用黄芪多糖注射液联合吉非替尼对肺癌患者组织降低Ki-67及提高P53蛋白表达的效果显著。
Objective To explore the effect of astragalus polysaccharide injection combined with gefitinib on tissue P53 and Ki-67 expressions in patients with lung cancer. Methods 67 cases of non-small cell lung cancer were selected and divided into two groups according to different therapy,control group of 28 cases received gefitinib orally,and study group of 39 cases received astragalus polysaccharide injection combined with gefitinib. The expressions of tissue P53 and Ki-67 were detected immunohistochemical method pre-and post-treatment and the T T lymphocyte subsets were detected at the same time. Results There were no significant difference in rates of effectiveness and disease control between study group and control group.Compared with control group,the positive rate of P53 was higher and the positive rate of Ki-67 was lower post-treatment in study group（ all P〈0. 05）.Compared with control group,the CD3~＋T and CD4~＋T were lower,the CD8~＋T,CD4~＋T / CD8~＋T were higher post-treatment in study group（ all P〈0. 05）. Conclusion The treatment of astragalus polysaccharide injection combined with gefitinib could significantly reduce tissue Ki-67 and increase tissue P53 expressions in patients with lung cancer.
出处
《中国生化药物杂志》
CAS
2016年第3期143-145,共3页
Chinese Journal of Biochemical Pharmaceutics
